In re CDC Corp.

484 B.R. 496, 2012 Bankr. LEXIS 5968, 57 Bankr. Ct. Dec. (CRR) 110, 2012 WL 6761566
United States Bankruptcy Court, N.D. Georgia·Decided December 28, 2012·No. No. 11-79079·Published

Opinion

ORDER ON APPLICATION FOR COMPENSATION OF MORGAN JOSEPH TRIARTISAN, LLC

PAUL W. BONAPFEL, Bankruptcy Judge.

The Official Committee of Equity Security Holders of CDC Corporation, the Chapter 11 debtor in this case, filed an application to retain Morgan Joseph TriArtisan, LLC as its financial advisor and investment banker. [Docket No. 109]. Under paragraph 2 of the engagement letter that the Court approved pursuant to 11 U.S.C. § 328(a), the Committee agreed that Morgan Joseph’s compensation would include a “Completion Fee” in the event of a “Shareholder Recovery.” [Docket No. 144].1 The Completion Fee is one percent of the first $100 million of the Shareholder Recovery, three percent of amounts in excess of $100 million and less than $200 million, and five percent of amounts over $200 million.

On September 6, 2012, the Court confirmed a Chapter 11 plan [Docket No. 542] that provides for the liquidation of the debtor’s assets, the payment of all claims and administrative expenses, and distribution of remaining proceeds to shareholders through the “CDC Liquidation Trust” that the plan establishes. [Docket No. 551], As a result of the liquidation of assets to date, shareholders currently are collectively receiving a distribution of almost $121 million. They will receive further distributions upon the liquidation of remaining assets and upon the resolution of disputed claims to the extent that the amounts allowed are less than the reserves set aside to pay them.

It is undisputed, therefore, that a Shareholder Recovery has occurred and that Morgan Joseph is entitled to a Completion Fee. The Debtor and the Committee, however, disagree with Morgan Joseph over how to determine the “Shareholder Recovery” on which the Completion Fee is based.

Morgan Joseph in its application for final compensation contends that the Shareholder Recovery is determined by reference to the average trading price of the [498]*498Debtor’s publicly trading shares in the five days preceding confirmation of the plan. (Morgan Joseph Application ¶¶ 25-30 [Docket No. 615] at 10-12). Based on an average trading price of $ 4.922 during this period and 39,004,624 outstanding shares, Morgan Joseph calculates the Shareholder Recovery as $191,980,759.30. (Id. at ¶ 27). This results in a Completion Fee of $ 3,759,423.2

The Debtor and the Committee contend that the Shareholder Recovery should be determined by reference to distributions actually made to shareholders under the plan through the CDC Liquidation Trust. (Debtor Objection ¶ 15 [Docket No. 664] at 4; Committee Objection ¶ 7 [Docket No. 665] at 4). Accordingly, they conclude that the Completion Fee currently due is $ 1,623,723.52, based on the distributions of $ 120,790,784 that shareholders have so far actually received. The Debtor and the Committee agree that Morgan Joseph will be entitled to additional fees as shareholders receive additional distributions.

The Court has entered a separate order approving payment of the undisputed portion of the Completion Fee, $1,623,723.52. [Docket No. 675].

Because the definition of “Shareholder Recovery” in paragraph 2 of the engagement letter governs resolution of the dispute, the Court quotes it at length [Docket No. 144 at 9-10]:

For purposes of this Agreement, “Shareholder Recovery” means the total fair market value of all consideration of any type or kind exceeding the amount required to pay (and that is paid or allocated for the purpose of paying) all allowed claims against the Company ... in full and in cash, that is distributed to holders of the Company’s Equity Securities (as defined in 11 U.S.C. § 101(16) (each a “Holder”).... Such consideration shall include, without limitation, cash, notes, securities and other property, payments made in installments, insurance recoveries, and Contingent Payments (as defined below). If any portion of the Shareholder Recovery is payable in the form of securities, the value of such securities for calculating the Completion Fee will be the average closing price for such securities for the five trading days prior to any distribution or allocation.... Any portion of any Completion Fee that is included within amounts that are paid into escrow or reserved subject to subsequent allowance or other Bankruptcy Court Order will be payable upon the establishment of such escrow or reserve. Contingent Payments other than escrowed or reserved amounts will be calculated based on the present value of the reasonably expected maximum amount of such Contingent Payments as determined in good faith by the Committee and Morgan Joseph, utilizing a discount rate equal to the prime rate published in The Wall Street Journal on the last business day before any distribution or allocation. If the parties cannot agree, the unpaid portion of any Completion Fee shall be paid to Morgan Joseph in the same proportions and at the same times as the Contingent Payments are paid. “Contingent Payments” shall be defined as the fair market value of any consideration in the form of deferred payments, performance-based payments, “earn-outs”, or other payments based on future events.

Morgan Joseph asserts that the provisions of paragraph 2 calling for valuation of securities based on average closing [499]*499prices governs determination of the Shareholder Recovery. It formulates its theory in various ways.

Morgan Joseph’s original application states, “The mandate of the Plan, while allowing the Debtor’s securities to remain tradable until consummation, makes the Debtor’s share closing price the best proxy for the amount of the Shareholder Recovery, and hence the amount of the Completion Fee.” (Morgan Joseph Application ¶¶ 26 [Docket No. 615] at 11). In its Reply in support of its application, Morgan Joseph asserts, “[T]he Engagement Letter is clear—a Shareholder Recovery is the fair market value of any consideration, of any type whatsoever, above that needed to pay creditors in full.” (Morgan Joseph Reply [Docket No. 666] at 4).

In its Supplemental Reply, Morgan Joseph states, “The Completion Fee, by its very terms, is based on the fair market value of consideration received or to be received by stockholders.... The Debtor’s stock price prior to the Effective Date was the exact proxy for the fair market value of the Beneficial Interests stockholders received, and thus is the fair market value of the total Shareholder Recovery under the Plan.” (Morgan Joseph Supplemental Reply [Docket No. 674] at 2). Later in the Supplemental Reply, Morgan Joseph notes, “[T]he Engagement Letter refers to the fair market value of the consideration that is the Shareholder Recovery, not the actual payouts to stockholders. There was a Shareholder Recovery, which occurred on the Effective Date.” (Morgan Joseph Supplemental Reply [Docket No. 674] at 7).

Although Morgan Joseph consistently describes its position as arising from the clear language of the engagement letter, nothing in its language requires or even permits determination of a “Shareholder Recovery” by reference to the average trading prices of the Debtor’s shares prior to confirmation in view of the confirmed plan’s provisions for distribution of cash to shareholders.

Free access — add to your briefcase to read the full text and ask questions with AI

In re CDC Corp., 484 B.R. 496, 2012 Bankr. LEXIS 5968, 57 Bankr. Ct. Dec. (CRR) 110, 2012 WL 6761566 (Ga. 2012).

484 B.R. 496 (In re CDC Corp.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related